BRIEF published on 07/08/2026 at 19:16, 3 months 23 days ago GenSight Biologics presents its financial situation and therapeutic advances Treasury GenSight Biologics Phase III RECOVER Early Access GS010/LUMEVOQ®
BRIEF published on 07/08/2026 at 19:16, 3 months 23 days ago GenSight Biologics Announces Cash Position and Business Updates Cash Position Clinical Trials Business Updates Early Access Programs Manufacturing Process
PRESS RELEASE published on 07/08/2026 at 19:11, 3 months 23 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position updates as of June 30, 2026, along with business developments, including proceeds from early access programs and manufacturing process improvements Cash Position Business Updates GenSight Biologics Early Access Programs Manufacturing Process
BRIEF published on 04/28/2026 at 20:40, 6 months 2 days ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
BRIEF published on 04/28/2026 at 20:40, 6 months 2 days ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
PRESS RELEASE published on 04/28/2026 at 20:35, 6 months 2 days ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 19, 2026, in Paris. Shareholders can access preparatory documents online. Meeting details and documents available on company website Annual General Meeting Shareholders Preparatory Documents Meeting Details GenSight Biologics
BRIEF published on 04/07/2026 at 19:04, 6 months 23 days ago GenSight Biologics Reports Cash Status and Early Access Revenues Revenue Cash Position Gene Therapy GenSight Biologics Early Access Program
BRIEF published on 04/07/2026 at 19:04, 6 months 23 days ago GenSight Biologics: Financial Update and Progress on AAC Fundraising Treasury Gene Therapy GenSight Biologics Compassionate Access
PRESS RELEASE published on 04/07/2026 at 18:59, 6 months 23 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 7 months 5 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
Published on 10/30/2026 at 23:35, 1 day 13 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 14 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 18 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 22 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 2 hours 59 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 8 hours 34 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 20 hours 59 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 14 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 14 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 1 hour ago Capital increase through exercise of subscription rights
